A detailed history of Fox Run Management, L.L.C. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 6,824 shares of NBIX stock, worth $931,680. This represents 0.18% of its overall portfolio holdings.

Number of Shares
6,824
Holding current value
$931,680
% of portfolio
0.18%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $781,893 - $1.05 Million
6,824 New
6,824 $785,000
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $481,697 - $530,975
3,694 New
3,694 $509,000
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $451,784 - $596,517
5,961 New
5,961 $581,000
Q1 2022

May 10, 2022

SELL
$72.45 - $94.81 $279,512 - $365,776
-3,858 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$79.65 - $106.22 $307,289 - $409,796
3,858 New
3,858 $329,000
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $260,694 - $299,565
-3,025 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$89.43 - $102.27 $270,525 - $309,366
3,025 New
3,025 $294,000
Q4 2020

Feb 08, 2021

SELL
$86.91 - $108.33 $248,475 - $309,715
-2,859 Closed
0 $0
Q3 2020

Oct 29, 2020

SELL
$96.16 - $135.15 $7,596 - $10,676
-79 Reduced 2.69%
2,859 $275,000
Q2 2020

Jul 31, 2020

BUY
$85.09 - $130.36 $249,994 - $382,997
2,938 New
2,938 $358,000
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $270,034 - $368,871
-3,111 Closed
0 $0
Q3 2019

Oct 15, 2019

SELL
$83.82 - $101.5 $123,969 - $150,118
-1,479 Reduced 32.22%
3,111 $280,000
Q2 2019

Jul 17, 2019

BUY
$72.24 - $91.27 $331,581 - $418,929
4,590 New
4,590 $388,000
Q1 2019

Oct 17, 2019

SELL
$69.31 - $91.53 $348,005 - $459,572
-5,021 Closed
0 $0
Q4 2018

Jan 15, 2019

BUY
$68.32 - $124.36 $213,158 - $388,003
3,120 Added 164.12%
5,021 $359,000
Q3 2018

Oct 05, 2018

BUY
$98.88 - $125.85 $187,970 - $239,240
1,901 New
1,901 $234,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.